Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

914
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
914
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

813
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
813
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diverging incidences of low-grade dysplasia and advanced neoplasia in inflammatory bowel disease: a nationwide Danish cohort study.

Scandinavian journal of gastroenterology·2026
Same author

Cytomegalovirus infection and coronary artery disease in liver transplant recipients: Nationwide study using protocolized cardiac computed tomography.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Cultural adaptation and validation for Brazilian portuguese of the MENTOR tool: monitoring the efficacy of neurogenic bowel treatment.

Spinal cord·2026
Same author

Effects of non-invasive spinal cord stimulation on autonomic function in individuals with subacute spinal cord injury: A pilot clinical trial protocol.

PloS one·2026
Same author

Evaluation of pan-alimentary MRI examinations: intrasubject variability and examination duration.

Abdominal radiology (New York)·2026
Same author

Survival and Tumour Microenvironment in Spatially Distinct Regions in Patients Resected for Hepatocellular Carcinoma: A Multicentre Study.

Journal of gastrointestinal cancer·2026

Related Experiment Video

Updated: Apr 22, 2026

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

1.7K

[Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].

Louise Størling1, Gerda Elisabeth Villadsen, Klaus Krogh

  • 1Klinisk Farmakologisk Afdeling, Bispebjerg -Hospital, Bispebjerg Bakke 23, 2400 København NV.

Ugeskrift for Laeger
|October 9, 2014
PubMed
Summary

Denosumab effectively treated bisphosphonate-refractory hypercalcemia in a patient with pancreatic neuroendocrine tumors. This suggests denosumab may be a potent alternative for malignancy-associated hypercalcemia.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

865

Related Experiment Videos

Last Updated: Apr 22, 2026

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

1.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

865

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Hypercalcemia is a common complication of malignancy, particularly neuroendocrine tumors.
  • Bisphosphonates are a standard treatment for hypercalcemia of malignancy but can be refractory.
  • Pancreatic neuroendocrine tumors (PNETs) can secrete calcium-regulating hormones, leading to hypercalcemia.

Observation:

  • A 48-year-old woman with a PNET presented with bisphosphonate-refractory hypercalcemia.
  • The patient received denosumab, a monoclonal antibody targeting RANKL.
  • A concurrent DOTATOC treatment was administered, which may have influenced calcium levels.

Findings:

  • Denosumab treatment led to a significant decline in plasma calcium concentration.
  • The patient's hypercalcemia resolved following denosumab administration.
  • Preliminary data suggest denosumab is more potent than bisphosphonates in treating malignancy-associated hypercalcemia.

Implications:

  • Denosumab represents a promising therapeutic option for bisphosphonate-refractory hypercalcemia.
  • This case highlights the potential of denosumab in managing complex endocrine-related complications of PNETs.
  • Further clinical trials are warranted to confirm the efficacy and safety of denosumab in malignancy-associated hypercalcemia.